The latest market report on ”Apixaban Market 2019” offers an in-depth analysis of this business vertical involving key information concerning industry deliverables, predominantly market tendencies, market size, market share, present valuation, and profits estimations for the estimate period. The brief information regarding the industry also analyzes and elucidates the Apixaban Market growth rate in the forecast timeline, incited by certain catalysts.
The following Top Leading Companies are: Pfizer, Medichem, Polpharma, Beijing Cooperate Pharmaceutical, Centaur Pharmaceutical, DEAFARMA, Dipharma Francis
(Exclusive Offer: Up to 20% discount on this report)
Get Sample Copy of this Report @
Apixaban is a Food and Drug Administrator (FDA) approved anticoagulant used for the treatment of venous thromboembolic events (blood clot) that forms within a vein. Venous thromboembolic events (VTE) can occur without any prior symptoms or warning signs and can go undiagnosed and unrecognized by a healthcare professional. Symptoms that do appear may be associated with pulmonary embolism (PE) or either deep vein thrombosis (DVT) such as pain in the calf, swelling in the ankle or foot, redness or noticeable discoloration spots, rapid breathing, chest pain, and others. Apixaban is sold under the trade-name of Eliquis. Factor Xa is a trypsin-like serine protease that plays a key role in blood coagulation cascade.
Apixaban mechanism works on inhibiting factor Xa, which indirectly decreases the clot formation stimulated by thrombin. Apixaban is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The recommended dose of Eliquis is 5mg orally twice a day. Apixaban is available in the market as capsules and tablet form.
Apixaban Market, by Types:
Apixaban Market, by Applications:
Avail Exclusive Discount on This Report:
Based on the region, the global apixaban market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America holds the dominant position in terms of revenue generated by the high price of the drug in treating venous thromboembolic events. For instance, according to GoodRx Inc. 2018 pricing detail, 60 tablets of Eliquis 5mg cost around US$ 524.38 on an average in the U.S. Moreover, increasing prevalence of venous thromboembolic events has boosted adoption of apixaban in North America market significantly. For instance, according to study published in the American Journal of Preventive Medicine in 2010, venous thromboembolism (VTE) affects approximately 300,000-600,000 people in the U.S. annually, causing considerable mortality.
Apixaban Market Global research report presents you analysis of market size, share, and growth, trends, and cost structure. The Report also presents an in-depth assessment of the Apixaban including enabling technologies, key trends, market drivers, challenges, standardization, opportunities, future roadmaps, value chains, ecosystem player profiles and strategies.
Buy This Report At:
Regional Analysis For Apixaban Market:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
The Reports Help Answer the Following Questions:
- What will be the market size and the growth rate in 2025?
- What are the key factors driving the Apixaban Market?
- Who are the key market players and what are their strategies in the Apixaban Market?
- What are the key market trends impacting the growth of the Apixaban Market?
- What trends, challenges and barriers are influencing its growth?
- What are the market opportunities and threats faced by the vendors in the Apixaban Market?
- What are the key outcomes of the five forces analysis of the Global Apixaban Market?
We also offer customization on reports based on specific client requirement:
1- Free country level analysis for any 5 countries of your choice.
2- Free Competitive analysis of any 5 key market players.
3- Free 40 analyst hours to cover any other data points
Irfan Tamboli (Head of Sales)
Phone: + 1704 266 3234